摘要
目的评价那格列奈和格列美脲治疗2型糖尿病的疗效及安全性,为临床提供用药参考。方法将48例2型糖尿病患者随机均分为那格列奈组和格列美脲组,疗程为12周。观察两组血糖、胰岛素、糖化血红蛋白(HbA1C)等变化及不良反应。结果两组患者治疗后空腹血糖、餐后2 h血糖和HbA1C均明显下降(P<0.05),两药降低空腹血糖的幅度无统计学意义,而那格列奈降低餐后2 h血糖和HbA1C的疗效优于格列美脲(P<0.05),那格列奈组餐后2 h血浆胰岛素浓度高于格列美脲(P<0.05)。结论那格列奈和格列美脲均能使空腹血糖明显降低,但那格列奈控制餐后2 h血糖和降低HbA1C的效果优于格列美脲。两药均较安全。
Objective To explore the effect and safety of nateglinide and glimepiride in treating type 2 diabetes to provide reference for clinical drug use.Methods Forty-eight patients with type 2 diabetes were divided into two groups randomly,the nateglinide group（n=24）and the glimepiride group（n=24）.The age,sex and clinical symptoms of two groups were matched.The treatment period was 12 weeks.The changes and adverse reactions of fasting blood glucose（FBG）,postprandial blood glucose（PBG）,insulin,HbA1C,etc.and adverse reactions were observed between the two groups.Results After the treatment,the levels of FBG,PBG and HbA1C in the two groups were descended significantly（P 0.05）.The decreasing range of FBG was not statistically significant between the two groups（P 0.05）.Nateglinide was more superior to glimepiride in reducing 2 h PBG and HbA1C（P 0.05）.The 2 h postprandial plasma concentration of insulin in nateglinide group was higher than that of glimepiride group.Conclusion Nateglinide and glimepiride all could reduce PBG,but nateglinide has more effects for controlling 2 h PBG and reducing HbA1C than glimepiride.Two drugs are safe.
出处
《中国药业》
CAS
2011年第1期68-69,共2页
China Pharmaceuticals
关键词
格列美脲
那格列奈
2型糖尿病
glimepiride
nateglihide
type 2 diabetes mellitus
